Table 2.
Comparison between groups of patients with laryngeal and/or hypopharyngeal SCC submitted to TL or TPL with HT or TT – clinic-epidemiological data.
| Variable | Thy Pos | Thy Neg | p-value |
|---|---|---|---|
| n (%) | n (%) | ||
| Gender | 1.000 | ||
| Male | 14 (93.3%) | 64 (94.1%) | |
| Female | 1 (6.7%) | 4 (5.9%) | |
| Current or past history of smoking | 1.000 | ||
| Yes | 14 (93.3%) | 60 (88.2%) | |
| No | 1 (6.7%) | 8 (11.8%) | |
| Primary site of the tumor | 0.728 | ||
| Larynx | 13 (86.7%) | 55 (80.9%) | |
| Hypopharynx | 2 (13.3%) | 13 (19.1%) | |
| T staginga | 0.129 | ||
| T 3 | 2 (0%) | 24 (35.3%) | |
| T 4a | 13 (100%) | 44 (54.7%) | |
| N staginga | |||
| N 0 | 8 (53.3%) | 37 (54.4%) | 1.000 |
| N 1 | 3 (20.0%) | 7 (10.3%) | 0.377 |
| N 2a | 1 (6.7%) | 7 (10.3%) | 1.000 |
| N 2b | 1 (6.7%) | 6 (8.8%) | 1.000 |
| N 2c | 1 (6.7%) | 10 (14.7%) | 0.679 |
| N 3 | 1 (6.7%) | 1 (1.5%) | 0.331 |
| M staginga | 1.000 | ||
| M 0 | 15 (100%) | 68 (100%) | |
| M 1 | 0 (0%) | 0 (0%) | |
| Global staginga | |||
| III | 1 (6.7%) | 14 (20.6%) | 0.2849 |
| IVa | 13 (86.7%) | 53 (77.9%) | 0.7248 |
| IVb | 1 (6.7%) | 1 (1.5%) | 0.331 |
| Performed surgery | 0.136 | ||
| TL/TPL + HT | 7 (46.7%) | 54 (79.4%) | |
| TL/TPL + TT | 8 (53.3%) | 24 (21.6%) | |
SCC, squamous cell carcinoma; TL, total laryngectomy; TPL, total pharyngolaryngectomy; HT, hemithyroidectomy; TT, total thyroidectomy; TL/TPL + HT, total laryngectomy or total pharyngolaryngectomy with hemithyroidectomy; TL/TPL + TT, total laryngectomy or total pharyngolaryngectomy with total thyroidectomy; Thy Pos, thyroid gland positive for malignancy; Thy Neg, thyroid gland negative for malignancy.
a
TNM and Global tumor staging, according to American Joint Committee on Cancer (AJCC) criteria.12